{"disease":{"id":"autosomal-dominant-hyper-ige-syndrome","name":"autosomal dominant hyper ige syndrome"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02996448","title":"Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}